Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00439179 · ClinicalTrials.gov registry record · Phase 1
A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema
A Phase 1 study of Metastatic Pancreatic Cancer, sponsored by Brown University.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT00439179 is a Phase 1 study of Metastatic Pancreatic Cancer that has completed, run by Brown University. The registered enrollment target is 27 participants, below the 106-participant average among 32 other Metastatic Pancreatic Cancer trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00439179, a Phase 1 study of Metastatic Pancreatic Cancer, has completed, sponsored by Brown University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase I Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema
Conditions Studied
Interventions
- DRUG cohort 1
- DRUG cohort 2
- DRUG cohort 3
- DRUG cohort 4
Study Locations (1)
Rhode Island
- Brown University Oncology Research Group - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2006-07 |
| Est. Completion | 2007-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00439179
The ClinicalTrials.gov registry entry for NCT00439179 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 106-participant average among 32 other Metastatic Pancreatic Cancer trials with a reported enrollment target (75% lower). The listed sponsor is Brown University, which has 231 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Pancreatic Cancer appearing as the primary indexed condition, and to 4 interventions - of which cohort 1 is the first listed.
NCT00439179 reports 1 study location spanning 1 distinct geographic area - top geographies include Rhode Island.
Frequently Asked Questions
What is clinical trial NCT00439179 about?
NCT00439179 is a clinical study titled "A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema". A Phase I Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema
What is the current status of trial NCT00439179?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2006-07. Estimated completion is 2007-12.
What conditions does trial NCT00439179 study?
This clinical trial studies the following conditions: Metastatic Pancreatic Cancer.
What interventions are being tested in trial NCT00439179?
The interventions under investigation include: cohort 1 (DRUG), cohort 2 (DRUG), cohort 3 (DRUG), cohort 4 (DRUG).
Who is sponsoring clinical trial NCT00439179?
This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00439179 being conducted?
This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer
RECRUITING · Phase 1
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
RECRUITING · Phase 1
-
Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC
RECRUITING · Phase 1
-
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.